Lantheus (NASDAQ:LNTH) Downgraded by ValuEngine

ValuEngine lowered shares of Lantheus (NASDAQ:LNTH) from a sell rating to a strong sell rating in a research report released on Thursday morning, ValuEngine reports.

A number of other brokerages have also commented on LNTH. Zacks Investment Research raised Lantheus from a sell rating to a hold rating in a report on Wednesday, September 25th. BidaskClub lowered Lantheus from a strong-buy rating to a buy rating in a report on Tuesday. Finally, CJS Securities raised Lantheus from a market perform rating to an outperform rating in a report on Friday, August 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $29.00.

NASDAQ LNTH traded up $0.31 on Thursday, reaching $19.74. The stock had a trading volume of 592,331 shares, compared to its average volume of 373,018. The company has a debt-to-equity ratio of 2.05, a current ratio of 2.62 and a quick ratio of 2.01. The firm has a fifty day moving average of $23.36 and a two-hundred day moving average of $24.86. Lantheus has a 1-year low of $12.59 and a 1-year high of $29.80. The company has a market cap of $763.59 million, a P/E ratio of 21.00, a price-to-earnings-growth ratio of 2.00 and a beta of 1.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $0.27 EPS for the quarter, meeting analysts’ consensus estimates of $0.27. Lantheus had a return on equity of 51.08% and a net margin of 11.20%. The firm had revenue of $85.70 million for the quarter, compared to analyst estimates of $88.72 million. During the same period in the prior year, the firm posted $0.25 EPS. The company’s revenue for the quarter was up .1% on a year-over-year basis. Research analysts predict that Lantheus will post 1 EPS for the current fiscal year.

In other news, Director Brian A. Markison sold 4,918 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $28.07, for a total transaction of $138,048.26. Following the sale, the director now directly owns 27,549 shares of the company’s stock, valued at approximately $773,300.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Tudor Brown sold 20,469 shares of the stock in a transaction on Friday, September 20th. The stock was sold at an average price of $24.93, for a total value of $510,292.17. Over the last three months, insiders have sold 124,024 shares of company stock worth $3,136,496. 2.60% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in LNTH. Quantamental Technologies LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth $56,000. Glen Harbor Capital Management LLC lifted its position in shares of Lantheus by 100.0% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 2,336 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 1,168 shares during the last quarter. Tyers Asset Management LLC lifted its position in shares of Lantheus by 100.0% during the 2nd quarter. Tyers Asset Management LLC now owns 3,212 shares of the medical equipment provider’s stock worth $91,000 after buying an additional 1,606 shares during the last quarter. Riverhead Capital Management LLC lifted its position in shares of Lantheus by 100.0% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,600 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 1,800 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Lantheus during the 2nd quarter worth $103,000. 95.72% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Story: Holder of Record

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.